Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck posted a modest Q4 earnings beat with adjusted EPS of $2.04 on $16.4 billion in revenue. ・The company is planning ...

Feb 4 (Reuters) - Some cancer therapies may be more effective when given earlier in the day, aligning treatment with the body ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...

Biomarker analyses provided proof of a mechanism during combination therapy.Yap and his colleagues observed increased CD8+ T cell infiltration and activation in tumors, reduced the regulatory T ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with the immunotherapy Keytruda (pembrolizumab), has been associated with a 49% ...

While Merck & Co.’s Keytruda already boasts a pair of approvals to treat certain forms of endometrial cancer, a recent effort to prove the PD-1 inhibitor’s worth as a post-surgery add-on therapy in ...

Keytruda did not significantly impact long-term health-related quality of life in stage 3 melanoma patients compared to placebo. Both Keytruda and placebo groups returned to baseline quality of life ...

Merck topped Q4 earnings and revenue estimates, helped by Keytruda and animal health growth, but its 2026 earnings and sales guidance came in below Wall Street expectations.

We came across a bullish thesis on Merck & Co., Inc. on R. Dennis’s Substack’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc.’s share was trading ...